The future of immunotherapy-based combinations for metastatic kidney cancer
The past decade or so has seen the development of [...]
Immunotherapy combinations standard of care for advanced kidney cancer
In 2015, the standard treatment for most patients with advanced [...]
Treatment of favourable-risk metastatic kidney cancer
The treatment of patients with intermediate- and poor-risk metastatic renal [...]
SMC approves lenvatinib plus everolimus combination for second-line treatment of advanced kidney cancer
We are delighted to announce that the Scottish Medicines Consortium (SMC), [...]
The effect of antibiotic use on outcomes with kidney cancer drug treatments
A recent study has looked at the use of antibiotics [...]
Effect of antibiotic use on outcomes with systemic therapies in metastatic kidney cancer
This study, published in European Urology Oncology this week, investigated [...]
ESMO 2019: Results from JAVELIN-Renal 101 trial for sarcomatoid kidney cancer
Results from the JAVELIN-Renal 101 clinical trial to assess avelumab [...]
Outcomes of metastatic kidney cancer patients treated with first-line immunotherapy and second-line VEGFR-TKI
The standard of care recommended for the treatment of patients [...]
Long term survival of patients with metastatic kidney cancer – a real world study
This real world study reports on the long term survival [...]
Low PD-L1 associated with long term response to sunitinib
Researchers from France have conducted a study to show that [...]
